A €15 million EU-funded trial will investigate phage therapy as an alternative to antibiotics for recurrent urinary tract infections. Researchers from 13 countries, including Hebrew University and Hadassah Medical Center, will evaluate personalized bacteriophage therapy to treat antibiotic-resistant E. coli infections.
Researchers found that CRISPR-Cas systems regulate the expression of innate immunity genes to defend against bacteriophages. This layered regulatory hierarchy provides a layer of protection, making it challenging for phages to evade the defense mechanisms.
Researchers discovered that CRISPR-Cas plays a broader role in bacteria, directing a network of innate immune systems. Over 20 innate defense modules are genomically embedded within type I CRISPR-Cas loci, which are kept under tight transcriptional control by small RNAs.
Scientists are conducting a European clinical trial aiming to reduce antibiotic use and lower recurrent urinary tract infection rates by targeting pathogenic E. coli strains with CRISPR-enhanced phage cocktails and microbiome restoration therapies.
A team of researchers from North Carolina State University has discovered a group of genetically stable viruses that infect an important plant pathogen. The findings suggest that these viruses could be used as tools to fight crop disease, and highlight the need for further research into viral diversity and evolution in agricultural set...
Researchers at Flinders University discovered that phage virus 'bioaugmentation' can enhance microbial function in polluted soils, allowing for faster degradation of pollutants. The method has potential for restoring polluted environments and promoting microbial resilience.
Bacteriophages, viruses that naturally infect bacteria, can be engineered into rapid and highly specific biosensors for clinical diagnosis, food safety, and environmental monitoring. These phage-based systems offer a compelling alternative to conventional methods, which often involve tradeoffs between speed, sensitivity, and cost.
A modular reporter phage platform has been developed to rapidly detect multiple Klebsiella pneumoniae capsule types. The platform uses a NanoLuc luciferase reporter gene and demonstrates high sensitivity and specificity, with the ability to distinguish between live and dead bacteria.
Researchers at McMaster University have developed a targeted approach to treating IBD using bacteriophages, which selectively target harmful bacteria without disrupting the gut ecosystem. The phage therapy significantly reduced gut inflammation and enhanced the effectiveness of steroid treatments.
A study identified molecular anchors on gut phages that enable them to attach to human cells and remain intact. The findings suggest that these proteins are evolutionarily advantageous strategies driven by modular phage surface proteins.
Researchers found that daunorubicin effectively inhibits bacteriophage infection in bacteria, triggering mutual destruction and killing the bacterial cell. The discovery opens up new avenues for phage therapy development, especially against antibiotic-resistant infections.
International experts will gather in Valencia to discuss phage therapy's translation from isolated successes to widespread clinical implementation. The challenge now is addressing regulation, manufacturing, accessibility, and clinical integration to make phage therapy a routine healthcare solution.
The center will develop new phage-based treatments for antibiotic-resistant bacterial infections, predicting which phage to use for which patient and designing more effective phages. The goal is to generate unprecedented data and train AI models to identify the right phage for any patient's infection.
China lacks a dedicated regulatory framework for phage therapy, but recent policy signals encourage development of standards and approval pathways. A three-pillared approach recommends national quality guidelines, phase-appropriate GMP pilot programs, clear product classification, and regional centers with reimbursement mechanisms.
Researchers identified how Mycobacterium abscessus evades treatment and proposed a strategy to overcome resistance, offering a pathway towards more effective treatments. A combination therapy targeting both smooth and rough variants proved more effective than single-phage treatment.
Scientists identify Lockin, Sequestin, and Acb5 protein families in phages, revealing how viruses silence bacterial immune systems. These findings shed light on the importance of communication disruption in the billion-year-long war between viruses and bacteria.
The Targeting Phage Therapy 2026 Congress will bring together experts to address clinical, regulatory, industrial, and hospital infrastructure requirements for phage therapy. The congress aims to move phage therapy from promising science to accessible, validated, and deployable medicine.
Monash University researchers have made a breakthrough in using phage therapy to treat life-threatening infectious diseases. The treatment involves injecting viruses called bacteriophages to kill bacterial infections that have not responded to other treatments.
Researchers at the John Innes Centre discovered a three-gene control hub that enables bacteria to share genes linked to antibiotic resistance. The study found that this mechanism is controlled by a bacterial immune system, which has been repurposed to release gene transfer agents.
A research team at HIRI discovered that CRISPR-Cas13 systems produce an RNA-based 'hairpin' structure to prevent the formation of waste RNAs, known as ecrRNAs. This mechanism optimizes the system's interaction and enhances its efficacy in immune defense and gene editing.
Researchers developed a machine learning model, DefensePredictor, to predict bacterial immune systems. The model identified hundreds of previously unknown immune systems and validated their function in 42 cases.
Research reveals that viruses can eavesdrop on each other using chemical signals, which may not always benefit the listener. This 'cross-talk' between species can lead to incorrect decision-making by the eavesdropper.
Researchers have identified phage W5 as a safe and effective natural virus capable of eliminating harmful Salmonella on various foods and packaging materials. The study establishes a solid foundation for developing novel phage-based disinfectants or preservatives to combat antibiotic resistance and enhance food safety.
The study reconstructs phage-viral operational taxonomic units and plasmids, linking them to microbial hosts using Hi-C sequencing. The results show that host community structure and biofilm architecture determine where these elements thrive, influencing nutrient cycling, antibiotic resistance, and biofilm resilience.
Researchers isolated and characterized a tiny phage from the human gut, revealing how bacteria and phages co-exist in an 'arms-race' through genetic heterogeneity. The study suggests that phage evolution can be harnessed for phage therapy to treat pathogenic bacterial infections.
Research reveals complex interactions between soil microbes, viruses, and microplastics, influencing soil health and ecosystem recovery. Innovations such as phage-assisted microbial augmentation aim to enhance plastic degradation in soils.
Scientists have discovered new ways to kill bacteria by targeting the MurJ transporter, a key component of peptidoglycan biosynthesis. Researchers found that phage-derived protein antibiotics inhibit MurJ's activity, providing potential targets for antibacterial drugs.
Scientists propose a solution to inactivate bacteriophages without destroying bacterial strains, using polymeric nanospheres that interact with phage surface charges. The nanoparticles are effective against 95% of phages and could provide a safer alternative to existing anti-phage strategies.
Researchers discovered a single protein, Rip1, that recognizes bacteriophages and causes infected bacteria to die prematurely. This protein works by forming a ring that inserts into the bacterial inner membrane, killing the cell before the infecting phage can replicate.
Researchers from New England Biolabs and Yale University have developed a first fully synthetic bacteriophage engineering system using the High-Complexity Golden Gate Assembly platform. This method simplifies strain engineering techniques, allowing for rapid creation of tailored therapeutic strains to overcome antibiotic resistance.
In a new study, terrestrial bacteria-infecting viruses were able to infect their E. coli hosts in near-weightless conditions aboard the ISS, but with distinct mutations. The dynamics of virus-bacteria interactions differed from those observed on Earth, highlighting potential insights into microbial adaptation and human health.
Researchers found that low doses of tetracycline, ampicillin, kanamycin, and streptomycin increase resistant bacteria and stabilize resistance through increased oxidative stress and membrane permeability. Long-term exposure to such low-level antibiotics leads to faster and more persistent expansion of resistant bacteria.
Researchers found that some phage-resistant mutations enhance bacteria's ability to sink carbon, while others slow down growth rates. The study suggests that the selection of surface mutants may play a key role in marine biological pump and carbon export.
Researchers discovered a tiny RNA molecule called PreS that helps viruses copy their DNA more efficiently and boost replication in bacterial cells. This discovery provides important insights for designing smarter phage-based therapies against antibiotic-resistant infections.
The study will select the exact phage that is appropriate for each patient's bacteria, and aims to reduce antibiotic use and healthcare costs. Bacteriophages have been shown to be effective against resistant bacteria causing urinary tract infections.
The discovery of five new bacteriophages in Lund University's Botanical Gardens' ponds has significant implications for phage research and treatment of bacterial infections. The newly-discovered phages were isolated using a motile E. coli strain, which was specifically designed to attract the viruses.
Researchers have catalogued a new collection of bacteria-eating viruses to combat the growing threat of hospital superbug Klebsiella pneumoniae. The open-source phage library offers scientists a valuable resource to develop new treatments and improve understanding of phages and bacteria interactions.
Researchers have created a detailed map of a bacteriophage, a virus that targets and kills harmful bacteria. The study's findings hold promise for developing new therapies to combat antibiotic resistance.
Researchers have mapped the full structure of bacteriophage Bas63 using cryo-EM, revealing unique decoration proteins and a rare whisker and collar structure. The detailed structural information will enable rational phage design and engineering efforts for specificity and target regions.
Scientists at the University of Pittsburgh have created phages with synthetic genetic material, allowing them to add and subtract genes. This breakthrough enables researchers to engineer phages to target specific bacteria, offering new hope for combating antibacterial resistance.
A literature review of cheese fermentation and ripening identified five underused, evidence-based measures to improve efficiency and sustainability in cheese production. By exploiting whey and encapsulating lactic acid bacteria, dairies can reduce waste and optimize production processes.
A multidisciplinary team has successfully mapped the entire genome of Phage G, a massive bacterial virus that can be grown in labs and studied directly. This achievement uses cutting-edge AI analysis to unlock new insights into phages and their applications in fighting disease.
Researchers are developing a precision phage platform to restore microbiome balance and combat antibiotic-resistant diseases. The MIGHTY project aims to harness phages as targeted antimicrobials, leveraging AI and machine learning methods to identify effective phage combinations.
Scientists develop novel experimental screening method to identify highly selective peptides with high therapeutic potential, enabling precise recognition of proteins involved in cancer and diabetes. The technique uses biologically- and chemically-modified bacteriophages to screen up to 1 billion peptides simultaneously.
Researchers from Monash University have developed Entelli-02, a five-phage cocktail specifically designed to target Enterobacter cloacae complex (ECC) bacteria. The treatment has shown promising results in reducing bacterial loads by over 99% in infected mice.
Researchers develop RNA-based molecular tool to interfere with phage replication, allowing for targeted therapy against bacterial pathogens. The approach has potential applications in treating infections caused by hospital germs like Pseudomonas aeruginosa.
A new way to fight drug-resistant infections has been discovered through the study of 'microbial piracy', where bacteriophages hijack other viruses to break into bacterial cells and spread. This could potentially be harnessed for medicine, offering a major route to tackling antimicrobial resistance.
Researchers are exploring the therapeutic potential of phage-based treatments, focusing on RNA phages that can hijack bacterial cell machinery and produce new phages. This study aims to elucidate the unique lifestyle of RNA phages and develop novel biotechnological tools for treating multi-resistant bacteria.
A recent study by Michigan Medicine researchers has found that CRISPR-Cas9 forms immune memories in bacteria by boosting spacer acquisition when RNA levels are low. This discovery expands our understanding of how bacteria safeguard their immune memory and may inspire new ways to design CRISPR-based molecular recording tools.
Researchers are collecting faeces from exotic animals at Dudley Zoo and West Midlands Safari Park to search for phages that can fight bacterial infections. The goal is to create a bio-bank of these phages to develop alternative treatments for life-threatening infections.
Researchers at the University of Waterloo have developed a novel method using modified M13 bacteria to deliver targeted gene therapies for genetic disorders. This approach shows promise as a cost-effective alternative to current methods, which can be expensive and trigger toxic side effects.
Researchers have identified a key defense mechanism in bacteria that protects them from viruses called phages, known as Kiwa. Phages are promising alternatives to antibiotics, but understanding how bacteria defend themselves is crucial to developing effective treatments.
Researchers found that immunocompromised animals respond better to phage therapy due to depleted alveolar macrophages, which initially seemed to hinder its efficacy. The study highlights the importance of the immune system in phage therapy and may inform personalized treatment strategies.
The gut virome, dominated by bacteriophages, regulates gut ecology and interacts with host immunity to influence the onset and progression of gastrointestinal diseases. Harnessing the virome through novel therapies, such as phage therapy and dietary modulation, may restore health and reduce disease severity.
Phage therapy is gaining recognition as a complementary tool to antibiotics, demonstrating potential in re-sensitizing resistant bacteria and extending antibiotic lifespan. Researchers are developing genetically customized phages for enhanced specificity and immune evasion mechanisms.
Researchers found that cholera bacteria acquired multiple distinct immune systems protecting them from diverse types of phages. These defense systems, including WonAB, GrwAB, and Vc SduA, contribute to the bacterial population's resistance spectrum.
Graham Hatfull, a renowned phage expert at Pitt, has been elected as a Fellow of the Royal Society, recognizing his contributions to the field of mycobacteriology. His lab's work on mycobacteriophages that kill bacteria and halt deadly infections has shown significant promise.
The international conference will focus on translating phage research into clinical reality, exploring key sessions and major speakers. Companies from various sectors are attending the event, highlighting the growing interest in phage therapy.
Sorek's work expanded understanding of how bacteria protect themselves from viruses, identifying dozens of previously unknown viral defense systems. His discoveries led to a better understanding of the human immune system and identified promising candidates for antiviral therapies.
Researchers uncover pivotal role of cyclic dinucleotides in triggering bacterial immune response, leading to rapid and robust activation of defenses. The study provides a unified model for how CDNs trigger membrane-targeting immune responses across diverse immune systems.